Kidney Med
The CURE-CKD Registry
Katherine R Tuttle, Lindsey M Kornowske, Cami R Jones, et al; CURE-CKD Consortium
This longitudinal, real-world cohort study was designed to use population-level data from health systems to identify IgA nephropathy and to assess risks. Noncommercial health insurance and greater care utilization could be used to help to identify individuals who may benefit from closer monitoring and therapeutic interventions.
Previous Article
- • Developments in Clinical and Translational IgAN Research
- • The CURE-CKD Registry
- • Non-Invasive Diagnostic Tools in IgA Nephropathy
- • Efficacy and Safety of Endothelin A Receptor Antagonists in IgA Nephropathy
- • Hydroxychloroquine Regulates Intestinal Flora and Glycosyltransferase Activity in Rats With IgA Nephropathy
- • Genetic Implications for IgA Nephropathy Therapy
- • Global Epidemiology of IgA Nephropathy
